Shell Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Shell Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$51K	Sell	6,737 -8,118	-55%	-$67.6K	0.01%	855
2025 Q2	$133K	Sell	14,855 -4,259	-22%	-$39.7K	﹤0.01%	913
2025 Q1	$143K	Sell	19,114 -320	-2%	-$2.58K	0.01%	911
2024 Q4	$146K	Hold	19,434	–	–	0.01%	945
2024 Q3	$148K	Buy	+19,434	New	+$148K	0.01%	940
2024 Q1	$127K	Buy	+20,557	New	+$116K	0.01%	957

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shell Asset Management's BCRX Position: Q3 2025 in Review

Shell Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 55% in Q3 2025, selling an estimated $67.6K and leaving 6,737 shares worth $51K. The position accounts for 0.01% of the portfolio, ranked #855.

Shell Asset Management first reported a position in BCRX in Q1 2024 and has held it in 6 quarters since. The position peaked at $148K in Q3 2024. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

Shell Asset Management held 6,737 shares of BioCryst Pharmaceuticals worth $51K as of Q3 2025.
Shell Asset Management sold 8,118 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $67.6K.
BioCryst Pharmaceuticals made up 0.01% of Shell Asset Management's portfolio in Q3 2025, its #855 holding.
Shell Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
Shell Asset Management's BioCryst Pharmaceuticals position peaked at $148K in Q3 2024.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.